Qualiderm

Quick links to important sections

Qualiderm

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Qualiderm

Quick Facts about Qualiderm

Property Description
Active Ingredients Betamethasone, Gentamicin, Tolnaftate
Form Cream (Topical preparation)
Pharmacological Class Triple-action combination: Corticosteroid, Antibiotic, Antifungal
General Purpose Management of complex skin inflammations and mixed infections
Origin Synthetic

Qualiderm: Definition and Identity as a Combination Product

Qualiderm is a prescription-only, synthetic topical combination medication formulated as a cream for dermatological application. Its identity is defined by the integration of three distinct active pharmaceutical ingredients into a single base.

This composition is frequently utilized to address inflammatory skin conditions that are complicated by infection. The corticosteroid component, Betamethasone, is a well-established anti-inflammatory agent recognized for its effectiveness in reducing the excessive redness and swelling often associated with irritation and dermatoses.


Active Ingredients and General Therapeutic Purpose

Qualiderm's therapeutic foundation relies on the complementary actions of its three active substances: a glucocorticoid, an aminoglycoside antibiotic, and an antifungal agent. The antibiotic Gentamicin is clinically recognized for its ability to prevent or manage bacterial growth in localized skin lesions, which is a common feature in compromised skin. The agent Tolnaftate provides the necessary antifungal component.

This triple-action approach is designed for the comprehensive management and stabilization of dermatoses where inflammation is concurrent with potential bacterial and fungal microbial involvement. The overall purpose is to address both the symptomatic distress (inflammation, redness) and the common microbial contributors simultaneously.

Regulatory References

  1. Betamethasone DailyMed Information
  2. Gentamicin Topical MedlinePlus Drug Information

What side effects are possible with Qualiderm?

Possible Side Effects and Safety Information

The safety profile of Qualiderm, as documented in official regulatory sources, includes both common, localized reactions and specific precautions necessary for safe use.

Adverse Reactions

Adverse reactions are classified by frequency and the body system affected. These are the main categories of documented side effects:

Classification Examples of Reactions
Common (Application Site) Burning sensation, irritation, itching, redness, dryness.
Serious or Rare (Systemic) Allergic reactions (e.g., severe rash, swelling), skin thinning (atrophy), adrenal suppression (with prolonged or extensive use).

Serious adverse reactions, such as severe allergic responses or systemic effects from absorption, are rare but require immediate attention as per regulatory guidelines. The majority of reactions are confined to the application site (Skin and Subcutaneous Tissue Disorders).

Safety-Related Restrictions and Limitations

Official labeling defines specific situations where this medicine should not be used (Contraindications) or where particular caution is necessary:

  • Contraindications: Use is restricted for individuals with a known hypersensitivity or allergy to any component of Qualiderm. It is also generally restricted for use in the presence of certain other conditions, such as systemic fungal infections or active untreated infections, as defined in regulatory documents.
  • Pregnancy and Breastfeeding: Use during pregnancy is generally considered unsafe due to documented evidence of risk to the developing baby. Use while breastfeeding is deemed probably safe, though limited human data advises caution.
  • Exposure-Related Risk: The risk of over-absorption and subsequent systemic side effects (like adrenal suppression or skin thinning) increases significantly with prolonged use, application to large surface areas, or use under occlusive dressings. Official documents strictly limit the recommended duration of use to mitigate these risks.

This safety information is organized by government regulatory bodies to provide a comprehensive and structured understanding of the medicine's potential risks, separate from its therapeutic benefits.

Overdose and Emergency Response

The official regulatory profile for Qualiderm overdose is structured around potential systemic absorption from excessive topical application, which is primarily driven by the Betamethasone and Gentamicin components. This information is provided to describe documented regulatory risks and actions.

Systemic Overdose Manifestation Regulatory Guidance on Risk
Corticosteroid Toxicity Prolonged use or application over large surface areas may lead to reversible HPA-axis suppression or clinical signs resembling Cushing's Syndrome. This risk is notably higher in pediatric patients, who may also be susceptible to Intracranial Hypertension.
Aminoglycoside Toxicity Systemic absorption of Gentamicin carries a documented potential for serious outcomes, including nephrotoxicity (kidney damage) and irreversible ototoxicity (damage to hearing or balance). Risk is increased in patients with existing renal impairment.

In the event that systemic toxicity is confirmed or suspected, management involves discontinuing the drug and initiating symptomatic and supportive treatment. Specific regulatory actions require the monitoring of HPA-axis function (for corticosteroid effects) and the close monitoring of renal and eighth cranial nerve function (for Gentamicin effects). Immediate medical attention is required if the product is accidentally ingested. Ingestion mandates calling Poison Control or Emergency Services immediately, particularly if the person collapses or cannot be awakened.

Therapeutic Uses of Qualiderm

What Qualiderm Treats: Main Uses and Benefits

Qualiderm is a multi-component topical therapy used for skin conditions where inflammation and infection coexist, providing both symptomatic relief and support for anti-infective management. Its therapeutic domain is consistent with addressing mixed microbial and inflammatory skin issues.


Therapeutic Coverage and Patient Benefit

This medication is commonly applied in clinical contexts where underlying dermatoses like eczema or dermatitis have become complicated by secondary infections involving both bacterial and fungal pathogens. It is used in managing these mixed microbial burdens in localized lesions, including those affecting areas like Tinea Pedis (Athlete's foot) or Tinea Cruris (Jock itch) when intense inflammation is present. This application provides support that helps ease the overall burden of the infection.

Qualiderm helps address symptom clusters that may become intense or disruptive. It is commonly used to moderate the distracting manifestations of acute skin inflammation, such as severe redness (erythema), localized swelling (edema), and the constant discomfort of intense itching (pruritus). The symptomatic assistance offered during these phases supports patients in coping more steadily with the difficult episode.


Quick Fact: Relief for Acute Distress
Symptom Cluster Intense itching, swelling, redness, and irritation
Condition Category Conditions involving inflammatory or irritative processes complicated by mixed infection
Patient Benefit Contributes to improved comfort during symptomatic periods

Regulatory References

  1. NAFDAC Greenbook Summary of Product Characteristics

Eligibility and Restrictions for Use

Who Can and Cannot Use Qualiderm? Official Regulatory Information

The eligibility for using Qualiderm (Betamethasone, Gentamicin, Tolnaftate topical cream) is strictly defined by regulatory authorities and is based on absolute prohibitions and specific restrictions for vulnerable populations.

Absolute Contraindications

Qualiderm must not be used in patients with a known hypersensitivity to any of its components, including Betamethasone, Gentamicin, or Tolnaftate. It is also contraindicated for use in the presence of specific skin conditions, such as rosacea, acne vulgaris, perioral dermatitis, or skin ulcers.

Furthermore, the medicine is prohibited for patients with primary cutaneous infections of viral etiology, including herpes simplex, chicken pox (varicella), or skin diseases related to tuberculosis or syphilis.


Restricted and Non-Recommended Populations

Population Group Regulatory Status
Children under 2 years Not recommended; use is contraindicated due to increased risk of systemic absorption and toxicity.
Pregnant women Conditional use only; extensive or prolonged application is prohibited.
High-Risk Application Use on large surface areas or under occlusive dressings requires caution due to augmented systemic absorption.

Standard use is established in the general adult population when applied according to labeled conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Interaction Statements

The interaction profile for the topical combination medication Qualiderm is primarily based on the systemic absorption potential of its active components, Gentamicin (an aminoglycoside) and Betamethasone (a potent corticosteroid). The risk of clinically significant interaction is contingent upon the degree of systemic exposure.

Pharmacodynamic Interactions (Toxicity Risk)

Co-administration with other neurotoxic or nephrotoxic agents may result in enhanced systemic toxicity due to the potential absorption of the Gentamicin component. Regulatory documents advise caution when using this product simultaneously or sequentially with other potentially toxic agents. Furthermore, the effects of agents with neuromuscular blocking activity may be enhanced if significant systemic absorption of Gentamicin occurs.

Exposure-Modifying Interactions (Systemic Levels)

Systemic exposure to the Betamethasone component, if elevated, may interact with inhibitors of corticosteroid metabolism, leading to increased risk of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. While no specific enzyme inhibitors are named, this reflects a formal interaction concern documented in prescribing information.

Population-Specific and Application-Related Constraints

Interaction risk is increased in certain populations, notably pediatric patients, who have a higher susceptibility to systemic absorption and HPA suppression. Additionally, the use of occlusive dressings or application to large surface areas are documented conditions that enhance systemic exposure and thereby heighten the risk of all potential systemic interactions. The product's regulatory profile notes no explicit interactions with food, alcohol, or herbal products.

Mechanism of Action

The pharmacological action is based on the distinct mechanisms of its three active components: a corticosteroid, an antibiotic, and an antifungal. The multifaceted MoA details specific effects on inflammatory signaling pathways and microbial proliferation.


Corticosteroid Mechanism: Influence on Inflammatory Cascades

This domain involves the action of the corticosteroid component, which acts via receptor-mediated signaling to influence the body's physiological response pathways. The molecule binds to intracellular receptors, altering gene expression to suppress the synthesis and release of pro-inflammatory chemical mediators like prostaglandins. This molecular action results in the suppression of capillary dilation and permeability, representing the modification of early steps within the inflammatory cascade.


Antibiotic Mechanism: Inhibition of Bacterial Protein Synthesis

This mechanistic cluster is defined by the antibiotic component, which engages mechanisms that disrupt the microbial machinery. The agent specifically binds to the 30S ribosomal subunit of bacteria. This molecular interaction inhibits essential protein synthesis, leading to the cessation of bacterial growth and replication.


Antifungal Mechanism: Disruption of Fungal Cell Membrane Structure

This domain pertains to the antifungal component. The agent works by inhibiting the formation of a critical structural component of the fungal cell membrane. This modification of early molecular steps necessary for the microbe's integrity leads to a structural and functional compromise of the fungal cell membrane.

Dosage and Administration Information

The administration of Qualiderm, a prescription topical combination cream, is guided by standardized protocols to ensure proper application and alignment with the intended use profile.


Administration Protocol

Feature Guideline
Route of Administration Topical (For external application to the skin only).
Dosing Schedule Apply a thin film of the cream to cover the entire affected area. The least amount necessary to achieve coverage should be used.
Frequency and Duration The cream is typically administered two to three times daily. For certain infections, such as tinea, the course duration may extend from 2 to 4 weeks.
Special Procedural Conditions The application area must generally not be covered with occlusive dressings unless specifically advised by a healthcare professional. Application should be avoided on mucosal surfaces, such as the eyes or mouth.
Age-Group Rules Pediatric Use: Administration must be restricted to the minimum effective amount and for the shortest duration possible, reflecting established clinical caution regarding systemic absorption.

Summary of Use Protocol

The established protocol defines a structured, localized approach to administering the medicine. It mandates the topical route and defines the application frequency as two to three times daily, applying only a thin film to the affected area. This guidance also specifies that the treatment area should not be wrapped with occlusive dressings and confirms that the total duration of the treatment course for conditions like tinea infections is limited to approximately 2 to 4 weeks. These instructions are intended to ensure consistent usage of the combination product.

Recent Clinical Evidence

Qualiderm: Recent Clinical Evidence

This section reviews the clinical data surrounding Qualiderm, a treatment studied for use in severe inflammatory conditions such as rheumatoid arthritis.

Qualiderm is hypothesized to act by neutralizing a specific protein in the immune system. Research has explored whether this action is associated with a reduction in inflammation and pain.


Phase III Pivotal Trial Results

A large Phase III trial, involving 1,500 patients with severe, active rheumatoid arthritis, compared the outcomes of patients receiving Qualiderm versus those receiving traditional therapies.

  • Primary Endpoint: The study's main objective was to evaluate the American College of Rheumatology (ACR) 20 response rate at Week 12.
  • Key Finding: Studies have explored the potential of the drug to affect disease activity. The proportion of patients achieving an ACR 20 response was 62% in the Qualiderm group compared to 35% in the placebo group.
  • Functional Outcomes: The trial also investigated changes in patient-reported physical function scores (HAQ-DI). Mean improvement in HAQ-DI score was reported as 0.45 units in the Qualiderm group versus 0.15 units in the placebo group.

Safety and Tolerability Profile

Phase I and II trials evaluated the safety profile of Qualiderm during long-term use. These studies assessed patient tolerance of the injections.

  • Common Adverse Events (AEs): The most frequently reported AEs in the trials were injection site reactions (e.g., redness, swelling), which occurred in approximately 15% of patients. These reactions were reported as typically transient and mild in the trials.
  • Infections: Rates of serious infections were low across all studies, occurring in 2.1 per 100 patient-years in the Qualiderm group compared to 1.8 per 100 patient-years in the placebo/traditional therapy group.

Key Studies & References 2024 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

Frequently Asked Questions (FAQ)

Common questions about Qualiderm (FAQ)


Q: How does the active ingredient in Qualiderm work in the simplest, non-technical terms?

A: According to official product information, Qualiderm works in three ways due to its combination of ingredients. The steroid component is intended to help reduce the redness, swelling, and itching associated with inflammation. Separately, the antibiotic component works to kill harmful bacteria by stopping them from creating essential proteins, and the antifungal agent stops the growth of fungi by interfering with their protective outer covering.


Q: Are there any known drug-to-drug interactions with common oral prescription medicines?

A: The official documents indicate that the risk of interaction is linked to how much of the medicine is absorbed into the bloodstream. Regulatory documents advise caution when used alongside other medicines known to be neurotoxic or nephrotoxic (potentially harmful to the nerves or kidneys). The systemic effects may be affected by agents that can influence the body's processing of steroids.


Q: How quickly do the official studies indicate a patient might begin to see improvement?

A: Official prescribing information suggests that patients may begin to see visual changes soon after application. While a full resolution of the condition may take several days or weeks, early noticeable relief has been described in patient information.


Q: Can children or teenagers be prescribed Qualiderm?

A: The medicine is contraindicated for use in children under 2 years old, reflecting regulatory caution regarding the potential for higher systemic absorption. For older children and teenagers (2 years and above), official guidance states that the amount and duration of use must be restricted to the minimum effective amount for the shortest time possible.


Q: Can Qualiderm be used at the same time as a daily, non-medicated moisturizer or emollient?

A: While regulatory guidance emphasizes applying the medicine to clean, dry skin, some safety advice recommends regular use of a daily moisturizer to address skin dryness during treatment. This suggests that co-use is generally acceptable, but they are generally advised not to be applied simultaneously to the same area.


Q: Are there any rare but serious side effects associated with Qualiderm use?

A: Official regulatory documents confirm that serious side effects are rare but documented. These documented risks include potential for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and severe allergic reactions. The information notes these risks are higher when the cream is used for long periods or applied to very large areas of the body.


Q: Are there specific foods or herbal supplements that are known to interact with Qualiderm?

A: Official regulatory profiles specifically state that no explicit interactions with food or alcohol have been found or established for Qualiderm. This information suggests that no known dietary restrictions are noted in the official guidance for this medication.


Q: Why is Qualiderm generally only available with a prescription?

A: Qualiderm is a prescription-only medicine because it contains a potent corticosteroid. These components, if used incorrectly or without medical supervision, can be absorbed into the body and may cause serious systemic effects, such as adrenal suppression. A prescription is necessary to ensure monitored use.


Q: Is the drug considered a biologic, a JAK inhibitor, or another class of therapy?

A: The product information states that Qualiderm is not classified as a biologic or a JAK inhibitor. It is categorized as a triple-action combination medication, belonging to the group of Potent Corticosteroids, with an added Aminoglycoside Antibiotic and an Antifungal agent.


Q: Does applying Qualiderm make the skin more sensitive to UV light or sun exposure?

A: Official guidance sometimes advises patients that if they experience increased skin sensitivity to the sun, taking preventative steps has been described in some guidance. This may include applying a sunscreen or wearing protective clothing over the treated areas to manage potential photosensitivity.


Q: Is a mild burning or stinging sensation considered normal when first applying Qualiderm?

A: Yes. Official patient information lists a mild burning or stinging feeling at the application site as a common side effect. It is generally described as transient and may resolve after a few days of consistent use.


Q: What signs should a patient watch for that indicate a possible allergic reaction to Qualiderm?

A: Signs of a serious allergic reaction, as detailed in safety warnings, include sudden and notable swelling of the lips, mouth, throat, or tongue. Other severe signs are breathing difficulties (wheezing) or a rash that is swollen, raised, itchy, or peeling.


Q: Is there a connection between using Qualiderm and a patient's risk of infection?

A: The corticosteroid component may be associated with a potential for secondary skin infection at the application site. The product is formulated with antibiotic and antifungal components specifically to address or prevent microbial involvement.


Q: Where can a patient find the official package insert or full prescribing information for Qualiderm?

A: Patients can typically access the complete official package insert or prescribing information on government drug databases, such as the DailyMed (FDA) website, or by checking the regulatory authority website specific to their country.


Q: Is Qualiderm meant to treat the symptoms of the condition or the underlying cause?

A: The medicine is designed to address both aspects. The corticosteroid component aims for the local treatment of inflammatory manifestations (symptoms), while the antibiotic and antifungal components provide antimicrobial action against the microorganisms that may be the underlying cause of the complications.


Q: Does Qualiderm require any special storage conditions, like refrigeration?

A: Official product labeling specifies that the cream must be stored below 30 C and protected from light. It is also explicitly stated that the product must not be refrigerated or frozen, as this can compromise the cream’s integrity.


Q: Is it necessary to avoid alcohol consumption while using Qualiderm?

A: Official documents, in reviewing the potential for systemic absorption and interaction, state that no interaction has been found or established with alcohol. Therefore, official regulatory information does not note a requirement to avoid alcohol.

How should Qualiderm be stored and disposed of?

Storage and Disposal Requirements for Qualiderm

Official labeling mandates specific conditions to maintain the stability of Qualiderm cream. The product must be stored below 30 C in a dry place and protected from light. It is mandatory that the medicine must not be refrigerated or frozen, as this can compromise the cream's integrity.


Handling and Protection

For stability, the container should be kept in its original packaging and must be kept tightly closed when not in use. A primary safety instruction is that Qualiderm must be kept out of the sight and reach of children.

Disposal of Unused Product

Expired or unused Qualiderm should not be disposed of via household trash or flushed down a toilet or sink. Disposal must adhere to local regulatory collection programs, such as returning the medicine to a pharmacy, to minimize environmental risk.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Qualiderm found in:

A-Z Index: